| LYB001 / Luye Group |
NCT05664932: Immunogenicity and Safety of COVID-19 Vaccine as a Booster Vaccination in Population Aged 18 Years and Above |
|
|
| Active, not recruiting | 3 | 1200 | RoW | Recombinant SARS-CoV-2 Vaccine (CHO Cell) LYB001, ZF2001 | Guangzhou Patronus Biotech Co., Ltd., Yantai Patronus Biotech Co., Ltd. | COVID-19 | 01/23 | 12/23 | | |
NCT05683600: Efficacy and Safety of COVID-19 Vaccine as Booster Vaccination in Adults 18 Years of Age or Older |
|
|
| Terminated | 3 | 3000 | RoW | Recombinant SARS-CoV-2 Vaccine (CHO Cell) LYB001, Placebo | Guangzhou Patronus Biotech Co., Ltd., Yantai Patronus Biotech Co., Ltd. | COVID-19 | 07/23 | 07/23 | | |
ChiCTR2100052039: Immunogenicity and safety of a SARS-CoV-2 vaccine LYB001 against COVID-19 in healthy adults: a randomized, double blinded, placebo-controlled phase II trial and a single-armed, open-label expanded safety phase III trial |
|
|
| Not yet recruiting | 2/3 | 1900 | | Low-dose LYB001: high dose LYB001: placebo=3:3:1 ;Low-dose LYB001: high dose LYB001: placebo=3:3:1 ;LYB001 | Mittaphab Hospital; Yantai Patronus Biotech Co., Ltd., Self-funded | Novel Coronavirus Pneumonia (COVID-19) | | | | |
NCT05137444: Phase Ⅱ and Ⅲ Trial of a SARS-CoV-2 Vaccine LYB001 |
|
|
| Not yet recruiting | 2/3 | 1900 | NA | LYB001, Placebo | Yantai Patronus Biotech Co., Ltd. | COVID-19 | 03/23 | 05/23 | | |
| Not yet recruiting | 2/3 | 18000 | NA | LYB001, Placebo | Yantai Patronus Biotech Co., Ltd. | COVID-19 | 12/23 | 02/24 | | |
NCT05663086: Immunogenicity and Safety of COVID-19 Vaccine in Population Aged 18 Years and Above |
|
|
| Withdrawn | 2 | 720 | RoW | One dose group, Two doses group, Aged 18-59 years, Aged 60 years old and above | Guangzhou Patronus Biotech Co., Ltd., Yantai Patronus Biotech Co., Ltd. | COVID-19 | 06/23 | 06/23 | | |
NCT05928455: The Immunogenicity and Safety Following a Heterologous Booster Dose of Recombinant SARS-CoV-2 Vaccine LYB001 |
|
|
| Active, not recruiting | 1 | 120 | RoW | LYB001, CoronaVac | Guangzhou Patronus Biotech Co., Ltd., Yantai Patronus Biotech Co., Ltd., Affiliated Hospital of North Sichuan Medical College | COVID-19, Vaccine Reaction | 10/22 | 06/23 | | |
NCT05552573: Safety and Immunogenicity of COVID-19 Vaccine in Population Aged 18 Years and Above |
|
|
| Active, not recruiting | 1 | 100 | RoW | low-dose LYB001, Recombinant COVID-19 Vaccine (CHO Cell), high-dose LYB001 | Guangzhou Patronus Biotech Co., Ltd., Yantai Patronus Biotech Co., Ltd. | COVID-19 | 01/23 | 12/23 | | |
NCT05125926: A Phase Ⅰ Trial to Evaluate the Safety and Immunogenicity of SARS-CoV-2 Vaccine LYB001 |
|
|
| Not yet recruiting | 1 | 100 | NA | LYB001, Placebo | Yantai Patronus Biotech Co., Ltd. | COVID-19 | 02/23 | 04/23 | | |
ChiCTR2100052040: Safety, Reactogenicity, and Immunogenicity of a Recombinant SARS-CoV-2 Vaccine LYB001 in Healthy Adults: A Randomized, Double Blinded, Placebo-Controlled Phase I Trial |
|
|
| Not yet recruiting | 1 | 100 | | LYB001: placebo=4:1, three dose at day 0, 28, 56 ;LYB001: placebo=4:1, three dose at day 0, 28, 56 ;LYB001: placebo=4:1, three dose at day 0, 28, 56 ;LYB001: placebo=4:1, three dose at day 0, 28, 56 | Mittaphab Hospital; Yantai Patronus Biotech Co., Ltd., Self-funded | Novel Coronavirus Pneumonia (COVID-19) | | | | |
